Physiomics PLC Prof. Mark Middleton appointed to Physiomics SAB (9498U)
August 04 2015 - 1:01AM
UK Regulatory
TIDMPYC
RNS Number : 9498U
Physiomics PLC
04 August 2015
Physiomics plc
("Physiomics") or ("the Company")
Professor Mark Middleton appointed to Physiomics SAB
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is pleased to announce that it has appointed Professor
Mark Middleton to its Scientific Advisory Board. Professor
Middleton is Professor of Experimental Cancer Medicine in the
Department of Oncology of the University of Oxford. He is an
eminent clinician with highly relevant clinical experience.
Mark is the Lead Cancer Clinician for the Oxford University
Hospitals NHS Trust and deputy director of the Cancer Research UK
Oxford Centre. He directs the EPCTU and the Cancer Theme of the
NIHR Biomedical Research Centre. Mark studied medicine at Cambridge
and Oxford and trained in medical oncology at the Christie
Hospital. He is a member of the International Melanoma Working
Group and of the NCRI Melanoma Clinical Studies Group. Mark leads
several clinical trials in the national portfolio, with an emphasis
on early phase trials of new drugs or drug combinations.
The directors believe that Mark's experience as a clinical
oncologist will be invaluable, particularly as the Company seeks to
access the stratified and personalised medicine market.
Dr Mark Chadwick, CEO of Physiomics, commented:
"We are delighted to welcome Professor Middleton to our SAB. His
undoubted knowledge and expertise will be invaluable to Physiomics
as we look to increase the number of clinical projects we undertake
and also seek to address the emerging market of stratified and
personalised medicine for cancer treatment."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAPKNDBABKDNFK
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024